Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treated with a statin~* Fasting LDL-C \>=100 mg/dL and triglyceride \<= 400 mg/dL~* High or very high risk of incurring a cardiovascular event~Exclusion Criteria:~* Pregnant or breastfeeding females~* Cardiovascular or cerebrovascular event or procedure within 90 days~* Congestive heart failure NYHA class IV~* Poorly controlled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bococizumab (PF-04950615; RN316) (Type: EXPERIMENTAL): Bococizumab (PF-04950615; RN316)
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).